H. Lundbeck A/S - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'H. Lundbeck A/S - Product Pipeline Review - 2016', provides an overview of the H. Lundbeck A/S's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by H. Lundbeck A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of H. Lundbeck A/S - The report provides overview of H. Lundbeck A/S including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses H. Lundbeck A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features H. Lundbeck A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate H. Lundbeck A/S's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for H. Lundbeck A/S - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding H. Lundbeck A/S's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 H. Lundbeck A/S Snapshot 6 H. Lundbeck A/S Overview 6 Key Information 6 Key Facts 6 H. Lundbeck A/S - Research and Development Overview 7 Key Therapeutic Areas 7 H. Lundbeck A/S - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 H. Lundbeck A/S - Pipeline Products Glance 15 H. Lundbeck A/S - Late Stage Pipeline Products 15 Filing rejected/Withdrawn Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 H. Lundbeck A/S - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 H. Lundbeck A/S - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 H. Lundbeck A/S - Drug Profiles 21 carbamazepine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 idalopirdine 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 LuAF-35700 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 nalmefene 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 vortioxetine hydrobromide 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 LuAF-11167 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LUAF-20513 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 LUAF-64280 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 AF-40431 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Brain Diseases 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules to Inhibit LRRK-2 for Parkinson's Disease 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 H. Lundbeck A/S - Pipeline Analysis 36 H. Lundbeck A/S - Pipeline Products by Target 36 H. Lundbeck A/S - Pipeline Products by Route of Administration 38 H. Lundbeck A/S - Pipeline Products by Molecule Type 39 H. Lundbeck A/S - Pipeline Products by Mechanism of Action 40 H. Lundbeck A/S - Recent Pipeline Updates 42 H. Lundbeck A/S - Dormant Projects 48 H. Lundbeck A/S - Discontinued Pipeline Products 49 Discontinued Pipeline Product Profiles 49 gaboxadol 49 LuAA-47070 49 idalopirdine 49 Lu-02750 50 Lu-35138 50 Lu-AA24493 50 LuAA-37096 50 LuAA-38466 50 LuAA-39959 50 LuAA-44608 51 LuAE-04621 51 ORE-10002 51 siramesine 51 tedatioxetine hydrobromide 51 vortioxetine hydrobromide 51 zicronapine 52 H. Lundbeck A/S - Company Statement 53 H. Lundbeck A/S - Locations And Subsidiaries 54 Head Office 54 Other Locations & Subsidiaries 54 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
H. Lundbeck A/S, Key Information 6 H. Lundbeck A/S, Key Facts 6 H. Lundbeck A/S - Pipeline by Indication, 2016 8 H. Lundbeck A/S - Pipeline by Stage of Development, 2016 9 H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016 10 H. Lundbeck A/S - Partnered Products in Pipeline, 2016 11 H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2016 12 H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016 13 H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016 14 H. Lundbeck A/S - Filing rejected/Withdrawn, 2016 15 H. Lundbeck A/S - Phase III, 2016 16 H. Lundbeck A/S - Phase II, 2016 17 H. Lundbeck A/S - Phase I, 2016 18 H. Lundbeck A/S - Preclinical, 2016 19 H. Lundbeck A/S - Discovery, 2016 20 H. Lundbeck A/S - Pipeline by Target, 2016 36 H. Lundbeck A/S - Pipeline by Route of Administration, 2016 38 H. Lundbeck A/S - Pipeline by Molecule Type, 2016 39 H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2016 40 H. Lundbeck A/S - Recent Pipeline Updates, 2016 42 H. Lundbeck A/S - Dormant Developmental Projects,2016 48 H. Lundbeck A/S - Discontinued Pipeline Products, 2016 49 H. Lundbeck A/S, Subsidiaries 54
List of Figures
H. Lundbeck A/S - Pipeline by Top 10 Indication, 2016 8 H. Lundbeck A/S - Pipeline by Stage of Development, 2016 9 H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016 10 H. Lundbeck A/S - Partnered Products in Pipeline, 2016 11 H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016 13 H. Lundbeck A/S - Pipeline by Top 10 Target, 2016 36 H. Lundbeck A/S - Pipeline by Route of Administration, 2016 38 H. Lundbeck A/S - Pipeline by Molecule Type, 2016 39 H. Lundbeck A/S - Pipeline Products by Top 10 Mechanism of Action, 2016 40
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population iRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from mainRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.